KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC

Summary

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics -

• Perception of Phase II mirikizumab induction data in UC


• Perception of mirikizumab’s Phase III study in UC


• Future expectations of mirikizumab in UC


• Future expectations for mirikizumab in Crohn’s disease

Key Highlights

• All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response


• Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab’s ongoing Phase III UC trial


• KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.

Scope

• The insight briefing is based on Sociable Pharma’s analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

• 5 Europe-based & 5 N. America-based


• Interviews performed during July 2018

KOL data is analyzed to produce -

• Charts summarizing KOL opinions


• Chart call-outs of key information & details


• KOL quotes


• Summary of KOL reporting trends


• Insight from Sociable Pharma's analysts

Reasons to Buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC


• Includes insight & recommendations from our disease-specific healthcare analysts


• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC


• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.